TrialThe oncologist2015
Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
Josep Tabernero et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
86 papers cite itlatest 60 shown
this paperpooled ittrialcites it